How is Melanotan I dosed and administered?

The name Melanotan I attaches to two very different things, and only one carries a real dosing standard. Afamelanotide, marketed as Scenesse, is the regulated pharmaceutical form, and its administration is a physician-placed controlled-release implant rather than a self-injected powder. The unapproved tanning products that borrow the name have no legitimate dosing protocol at all.

What pharmaceutical form does the approved version of afamelanotide take?

The approved afamelanotide product is not a vial of powder waiting to be measured, but a solid, rod-shaped implant about the size of a grain of rice. Its dose is fixed at manufacture and dispersed in a bioresorbable polymer that releases the peptide over several days. That fixed-unit design is the first feature separating the labeled drug from a reconstituted injection.

• Physical form: A solid rod roughly 1.5 cm long and 1.5 mm wide, comparable to a grain of rice.
• Release matrix: The peptide sits in a bioresorbable poly-DL-lactide-co-glycolide polymer that dissolves as it releases.
• Fixed dose: Each implant carries a factory-set quantity of afamelanotide on the order of 16 mg, not drawn up by the clinician.
• Handling: The unit arrives pre-loaded in a sterile single-use applicator, handled under aseptic technique.

Who is authorized to place the product and in what clinical setting?

Placement of the implant is confined to physicians who complete a manufacturer-directed accreditation program, which keeps the procedure out of general or self-administered use. The controlled-distribution model ties supply to accredited prescribers rather than to individual patients. In practice the treatment runs through porphyria expert centers and academic units that already manage the underlying disease.

• Accredited placement: Only physicians trained through the manufacturer's accreditation program in patient selection and insertion technique are authorized to place it.
• Specialist setting: Delivery happens through porphyria expert centers or academic dermatology and hepatology units.
• Insertion site: The accepted technique places the implant subcutaneously above the iliac crest after local anesthetic infiltration.
• Controlled distribution: Supply is tied to accredited centers, so a patient cannot obtain and place the implant independently.

What dosing schedule does the regulatory labeling specify for the approved indication?

The core of the labeled schedule is one implant approximately every two months during the part of the year when protection is needed. The peptide releases over the first several days, but its effect on protective pigmentation lasts weeks, which is what supports the two-month interval rather than a shorter one. The interval is set by the release matrix and the durability of the response, not by patient preference.

1. First implant: Placement begins before the higher-light months so protective pigmentation is established as light intensity rises.
2. Bimonthly interval: Under FDA labeling each subsequent implant follows at roughly two-month spacing, individualized to the patient's exposure period.
3. No fixed annual cap: The labeling specifies dosing every two months and does not set a maximum number of implants per year.
4. Fixed pace: The interval reflects the release biology and response durability, so it is not shortened to intensify the effect.

Which condition is the approved administration intended to treat?

The approved administration is built entirely around one rare inherited disease: erythropoietic protoporphyria. In this disorder an enzyme deficiency in the heme pathway lets protoporphyrin IX accumulate in red blood cells and skin, and when light reaches it the resulting reactive oxygen species cause intense burning pain rather than an ordinary tan or sunburn. Afamelanotide raises photoprotective pigment and the threshold at which that reaction begins.

• Underlying defect: An enzyme deficiency in the heme pathway causes protoporphyrin IX to accumulate in red blood cells and skin.
• Phototoxic reaction: Light striking the accumulated protoporphyrin generates reactive oxygen species, producing severe burning pain and swelling.
• Drug mechanism: Afamelanotide, an alpha-melanocyte-stimulating hormone analogue, binds the melanocortin-1 receptor and increases photoprotective eumelanin.
• Eligible population: Labeling confines use to adults with a confirmed diagnosis, a condition affecting only a few people per hundred thousand.

How does controlled-release subcutaneous delivery differ from injectable peptide administration?

The difference between the implant and a self-drawn injection is not mainly the route, it is the shape of the exposure curve. A depot implant meters the peptide out gradually for a smooth, sustained level, where a repeated bolus injection produces a saw-tooth of high peaks and low troughs. Dose-related effects and side effects tend to concentrate at those peaks.

What clinical monitoring accompanies each dosing cycle?

Each dosing cycle sits inside a monitoring routine that starts before placement and runs through the interval that follows. Because the drug increases melanocyte activity and pigmentation, product information calls for regular whole-body skin examination to watch pigmented lesions and moles over the course of treatment. That wrap-around oversight is only possible in a specialist setting.

1. Before placement: The clinician assesses the skin and the intended insertion site.
2. Skin surveillance: Product information advises regular whole-body skin examination of pigmented lesions and moles during treatment.
3. Site check: After placement the site is observed for the expected minor local reaction and for any sign of infection or migration.
4. Response tracking: Across the season, benefit is gauged by more pain-free time in light and fewer phototoxic episodes.
5. Stop criteria: A suspicious or changing lesion, poor response, or adverse effects outweighing benefit prompt reassessment, pausing, or stopping.

Why do unregulated self-injected tanning products fall outside any approved dosing framework?

The self-injected tanning products sharing the Melanotan I name fall outside any approved dosing framework because none of the conditions that make a dose meaningful are present. Their purity and even their true peptide identity are unverified, so a number printed on a vial label is not a validated dose. Without a quality-controlled manufactured unit there is no reference quantity to dose against.

• Unverified content: Purity and true peptide identity are unconfirmed, so the actual active amount in a vial is unknown.
• No reference unit: Absent a manufactured, quality-controlled unit, the milligram figures circulated in these communities carry no clinical standing.
• Sterility risk: Reconstituting powder at home introduces contamination risks that licensed manufacturing is designed to eliminate.
• No oversight or legal status: Sold as research chemicals or unlicensed goods in most markets, with none of the monitoring or stop rules that surround the approved implant.

How is the timing of administration tied to seasonal light exposure?

Timing is anchored to when the patient actually faces harmful light, so the schedule is built around the higher-sunlight portion of the year rather than the calendar in the abstract. The first implant is generally placed shortly before that season begins, so pigmentation is established before light intensity peaks. Because the relevant variable is real exposure, the calendar shifts with geography.